Hydrofarm Group (HYFM) Q3 2025 earnings summary

Executive summary

• Net sales declined 33.3% year-over-year to $29.4 million in Q3 2025, primarily due to industry oversupply and reduced cultivation activity, resulting in a net loss of $16.4 million for the quarter.

• Restructuring efforts in 2023 and 2025 focused on streamlining operations, reducing costs, and improving efficiency, with further actions anticipated if adverse market conditions persist.

• Proprietary brand mix increased, supporting a shift toward higher-margin products, but lower manufacturing volume negatively impacted adjusted gross profit margin.

• CEO transition announced, with Bill Toler resuming the CEO role effective December 1, 2025.

• The business continues to face headwinds from industry oversupply, slow regulatory reform, and tariff uncertainties impacting demand and financial performance.

Financial highlights

• Q3 2025 net sales were $29.4M, down from $44.0M in Q3 2024, with a net loss of $16.4M and gross profit margin declining to 11.6% from 19.4% year-over-year.

• Adjusted gross profit was $5.5M (18.8% of net sales), compared to $10.7M (24.3%) in Q3 2024.

• Adjusted SG&A was $9.9M, a 7.4% year-over-year reduction, and adjusted EBITDA was $(4.4)M, down from $0.02M in Q3 2024.

• Free cash flow for Q3 2025 was nearly break-even, a $5.1M improvement year-over-year.

• Cash and cash equivalents were $10.7M at September 30, 2025, with $4M available on the revolver and $114.5M in term loan principal outstanding.

Outlook and guidance

• Full year 2025 adjusted gross profit margin expected to be approximately 20%, with continued year-over-year reduction in adjusted SG&A expense.

• Management anticipates up to $2M in additional restructuring charges and annual cost savings of $5M, plus working capital benefits from the 2025 Restructuring Plan.

• Positive free cash flow and inventory reduction expected for the final nine months of 2025.

• Capital expenditures projected to be less than $2M for 2025.

• Ongoing industry headwinds, tariff uncertainties, and slow regulatory changes may impact product costs and performance.